In October 2007, the FDA introduced that the labeling for all PDE5 inhibitors, together with tadalafil, needs a more outstanding warning with the opportunity threat of sudden Listening to reduction as the results of publish-marketing experiences of non permanent deafness linked to usage of PDE5 inhibitors.[19]Coronary heart issues. Sexual exercise